July / August 2019
Features
Case for consistent treatment of DR, DME
Data from clinical trials and real-world findings suggest early and regular treatment provides optimal outcomes.
Protocol V, ERM biomarker, AI and injection for GA
The case for observation in CI-DME, DRIL in ERM surgery, AI to predict HbA1c and screen for DR, and a subcutaneous mitochondrial agent.
Regression following IVT anti-VEGF in ROP
A review of disease progression patterns and the role for laser ablative therapy and intravitreal bevacizumab therapy.
The promise and pitfalls of suprachoroidal dosing
Investigational suprachoroidal delivery platforms have leveraged excellent bioavailability with favorable safety signals.
Scleral buckling surgery: As vital as ever
A review of modern techniques and indications for the repair of rhegmatogenous retinal detachments.
Departments
Clinical Trial Closeup
Modulating macrophages to target GA
Investigational candidate aims to change macrophage behavior in management of dry age-related macular degeneration.
Editor's Page
Innovation Insight
AMD is gene therapy’s emerging darling
Most programs in retinal disease still target inherited disorders, but both wet and dry forms of age-related macular degeneration are attracting interest.
News
Retina CEO
Arm yourself for payer negotiations
Uphill battle or slippery slope? These ideas can give you solid footing when seeking better reimbursement terms.
Surgical Pearl Video
The Yamane technique optimized
A modification of the highly regarded approach to intraocular lens scleral fixation.
Current Issue
Continuing Medical Education
Additional Publications
Tuesday, October 8, 2024 | Learn More About Stargardt Disease
Location: Webinar
Time: 7:00 PM ET
Time: 7:00 PM ET
Speaker: Lejla Vajzovic, MD, FASRS
Sponsored by Alkeus Pharmaceuticals, Inc.
Earlier Treatment Can Matter for Macular Edema Following Retinal Vein Occlusion
Treating Chronic Inflammation Associated With Uveitis Affecting the Posterior Segment in a Retina Setting with YUTIQ
GA: Recognizing the Burden
Treatment of Proliferative Diabetic Retinopathy
Improving Wet AMD Outcomes With a Fellow Eye Strategy
